Japan’s Major Generic Drug Makers Sawai And Towa To Launch Batches Of Products
This article was originally published in PharmAsia News
Executive Summary
Japan's largest generic drug maker Saiwai will launch 34 products after May, including anticancer, ulcer and pollakiuria drugs. The launch is a 7 percent increase compared to last year. Sawai's production capacity also increased by 30 percent compared to 2007. Rival Japanese generic drug maker Towa Pharmaceutical plans to launch 14 products including anti-infection drugs. To promote the products, Towa has increased staff members to provide information to medical facilities. (Click here for more - Japanese language
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.